Study	Numbers in trial Treatment groups	Any adverse event	Serious adverse event
NCT00350103	N = 551 LCM 400 mg StT, n = 181 LCM 400 mg FT, n = 189 Placebo, n = 179	No usable data	LCM 400: 28/370 Placebo: 14/179
NCT00401830	N = 159 LCM 400 mg, n = 78 Placebo, n = 81	LCM 400: 53/78 Placebo: 40/81	LCM 400: 0/78 Placebo: 3/81
Rauck 2007	N = 119 LCM 400 mg, n = 60 Placebo, n = 59	LCM 400: 52/60 Placebo: 44/59	No data
Shaibani 2009	N = 468 LCM 200 mg, n = 141 LCM 400 mg, n = 125 LCM 600 mg, n = 137 Placebo, n = 65	LCM 200: 113/141 LCM 400: 99/125 LCM 600: 119/137 Placebo: 55/65	LCM 200: 7/141 LCM 400: 6/125 LCM 600: 9/137 Placebo: 4/65
Wymer 2009	N = 370 LCM 200 mg, n = 93 LCM 400 mg, n = 91 LCM 600 mg, n = 93 Placebo, n = 93	LCM 200: 70/93 LCM 400: 71/91 LCM 600: 83/93 Placebo: 73/93	LCM 200: 3/93 LCM 400: 9/91 LCM 600: 9/93 Placebo: 7/93
Ziegler 2010	N = 357 LCM 400 mg StT, n = 73 LCM 400 mg SlT, n = 77 LCM 600 mg, n = 133 Placebo, n = 73	LCM 400: 88/149 LCM 600: 86/133 Placebo: 40/73	LCM 400: 11/149 LCM 600: 11/133 Placebo: 3/73
LCM ‐ lacosamide; FT ‐ fast titration; SlT ‐ slow titration; StT ‐ standard titration